Bayer received EU marketing authorization for Beyonttra (acoramidis) to treat transthyretin amyloidosis with cardiomyopathy (ATTR-CM), following positive Phase III results showing reduced mortality and hospitalizations. This oral drug stabilizes transthyretin and slows disease progression, complementing its U.S. FDA approval in November 2024. Bayer holds exclusive marketing rights for Beyonttra in Europe, with a launch expected in early 2025. The approval strengthens Bayer’s pharma portfolio amid revenue pressures, positioning it to compete with Pfizer’s Vyndaqel and capture share in the growing ATTR-CM market, projected to reach EUR 5bn by 2030 in EU alone. Despite financial challenges, Bayer’s successful R&D execution with Beyonttra underscores its strategic focus on high-margin specialty and rare diseases, positioning the company for a strong return to growth in its pharmaceutical segment by 2027. mwb research’s analysts maintain their BUY with an unchanged PT of EUR 31.00. The full update can be downloaded under https://www.research-hub.de/companies/Bayer%20AG

Verbio SE announced better-than-expected Q2 24/25 results, with revenues down yoy but EBITDA exceeding forecasts. The Biodiesel segment showed stable sales and strong EBITDA growth, driven by favorable rapeseed oil margins. In contrast, the Bioethanol/Biomethane segment saw a revenue drop and a larger EBITDA loss, impacted by lower prices and changes in financial assets. Verbio revised its FY24/25 EBITDA guidance in January due to technical issues at its US facility and ongoing pressure from low GHG prices. The company now expects mid-double-digit EURm in EBITDA. Despite these hurdles, management remains optimistic about a 2025 recovery, driven by growing demand for CO2 savings and stricter regulations outside Europe. Verbio’s long-term outlook remains positive, with US expansion a key growth driver. mwb research’s analysts maintain their BUY rating with a PT of EUR 16.00. Register here to join the earnings call today at 14:00 (MEZ): https://research-hub.de/events/registration/2025-02-12-14-00/VBK-GR. The full update can be downloaded under https://www.research-hub.de/companies/Verbio%20SE

Ceconomy began FY24/25 with strong momentum, outperforming the market. While underlying growth was fueled by solid performances in brick-and-mortar and online channels, with Retail Media and Marketplace scaling rapidly, new Xpress and Smart stores and acquisitions in Germany and Switzerland expanded the company’s footprint. Operating profit improved through better cost control, with DACH leading and Italy showing recovery. Despite challenges in Poland, Ceconomy is addressing competitive pressures. Effective inventory management boosted free cash flow, supporting strong holiday sales. While the FY outlook has been confirmed, Ceconomy remains on a solid path. mwb research’s analysts raise their price target to EUR 3.75 (EUR 3.50) and maintain their BUY rating. The full update can be downloaded under https://www.research-hub.de/companies/Ceconomy%20AG

Amadeus Fire reported prelim. results for Q4/FY24, showing resilience (FY revenues down only 1.2% yoy) in the face of challenging economic conditions. However, Q4 showed a more pronounced decline of 11% yoy, highlighting the ongoing (and deteriorating) negative sentiment among German businesses and political uncertainties. The operating gross profit margin declined by 80 bps to 54.2%, resulting in a 3% yoy decline in operating gross profit. Nevertheless, EBITA declined by c. 21% yoy to EUR 55.5m, slightly below the company's guidance of EUR 58m, as Amadeus has limited scope to adjust costs, and if so, only with a time lag. Looking ahead, the negative sentiment in Germany is likely to persist, potentially setting the company up for another weak financial year. However, bold investors should be able to capture some upside optionality, as the analysts of mwb research believe most of the weaknesses are already priced into Amadeus' share price. The analysts therefore reiterate their BUY rating with an unchanged PT of EUR 105.00. The full update can be found on https://www.research-hub.de/companies/Amadeus%20FiRe%20AG

Nemetschek’s Investor Relations manager, Patrick Horch, participated in mwb research’s well-attended ‘Focus on IT’ conference, providing insights into the company’s latest business developments. A recording of the presentation can be found here: mwb research | Digital ResearchHub | Equity Research. Nemetschek is capitalizing on the digital transformation of the construction and design software industry, leveraging AI integration and a diversified revenue base across key segments. Preliminary FY24 results show a 17% yoy revenue increase to EUR 996m, driven by strong organic growth and the GoCanvas acquisition, with recurring revenues now exceeding 86% due to the transition to SaaS. The successful integration of GoCanvas reduces the dependency on European markets and is expected to improve profitability in the medium term. Despite the price target increase to EUR 117.00 (old EUR 110.00), the HOLD rating is maintained due to limited near-term catalysts and a rich valuation. The full update can be downloaded under https://www.research-hub.de/companies/research/Nemetschek%20SE

Gerresheimer (GXI) has confirmed that it is in preliminary discussions with private equity investors. According to GXI, these investors have expressed an interest in exploring a possible public takeover offer on a non-binding basis. In mwb research’s view, this is a clear sign that the mostly US-based investors consider German SMEs to be undervalued. In mwb research’s believes, GXI is an attractive target that trades well below its peer group valuation (EV/EBIT '25 of 14x vs. 24x peer median). For a successful takeover, PE investors would have to offer a premium that the analysts believe should be at least 30% above the 3-months volume-weighted average price of EUR 74.38. With estimates unchanged, the analysts reiterate their BUY rating with a price target of EUR 96.00. The full update can be downloaded under https://www.research-hub.de/companies/research/Gerresheimer%20AG

Following the chip shortage crisis, the automotive semiconductor cycle peaked in late 2023 and entered a correction phase in 2024, marked by inventory gluts and muted chip orders. This is expected to persist through H1 2025, with gradual recovery anticipated in H2 2025 and a new growth cycle to begin in 2026 driven by structural trends. Modest price erosion of 2-3% is expected as supply chains normalize. Mwb research’s analysts have already factored in the impact on Elmos and yet remain confidently bullish at current valuations heading into 2025. Elmos outperformed its peers during the 2024 downturn, and the analysts expect this momentum to continue as the market recovers. mwb research’s analysts reiterate their BUY rating with a PT of EUR 98.00. The full update can be downloaded under https://research-hub.de/companies/Elmos%20Semiconductor%20SE

Airbus is grappling with multiple headwinds that undermine its growth prospects and valuation. The significant delay of its hydrogen-powered ZEROe project, now potentially pushed from 2035 to 2045, not only stalls its efforts in sustainable aviation but also erodes a key pillar of its long-term growth strategy under the net-zero agenda. This delay, combined with the discontinuation of its Beluga Transport operations, highlights broader operational and innovation challenges. Financially, Airbus is struggling with a ROCE of just 8%, barely covering capital costs, while facing intensified competition from COMAC, whose rapid production expansion threatens Airbus’s margins and market share. A sharp 72% drop in gross orders further signals the end of the post-pandemic recovery cycle. With 51% of the DCF valuation tied to terminal value—highly sensitive to these negative developments—the stock appears significantly overvalued. mwb research’s analysts therefore maintain their SELL rating and a price target of EUR 127.00, urging investors to take profits amid growing risks. The full update can be downloaded under https://www.research-hub.de/companies/Airbus%20SE

Siemens Healthineers AG’s (SHL) Q1 FY25 results were better than market expectations. Revenues grew 5.7% yoy on a comparable (comp.) basis, ahead of consensus of +3.6% yoy, with growth across all segments. Order intake was robust, with the equipment book-to-bill ratio at an impressive 1.21x in Q1 (FY 24: 1.11x). Adj. EBIT grew 11% yoy to EUR 822m (a 2% beat), and the margin improved 70bps yoy to 15.0%, led by the Diagnostics and Varian businesses. With a good start to FY25, management reiterated its full-year guidance. Order book remains healthy, and except China, most regions are witnessing positive demand trends, and savings from the Diagnostic business’ transformation are coming through. This underscores our belief that SHL will continue to benefit from structural mega-trends in the MedTech industry, given its strong market position. mwb research’s analysts slightly increase their estimates and PT to EUR 64.00 (old: EUR 60.00). The analysts maintain their BUY rating on the stock. The full update can be downloaded under https://www.research-hub.de/companies/research/Siemens%20Healthineers%20AG

Cancom's Head of Investor Relations, Lars Dannenberg, participated in mwb research’s well-attended ‘Focus on IT’ conference, providing insights into the company’s latest business developments. A recording of the presentation can be found here: research-hub.de/videos. While short-term headwinds from macroeconomic pressures persist, Cancom’s strategic investments in digital transformation and service diversification position Cancom well for sustainable long-term growth. The company's robust market position (#5 in DACH region), strong M&A track record, and focus on high-growth IT segments such as cloud computing, cybersecurity, and AI support our optimistic outlook. The preliminary FY24 numbers due on February 11 will provide more insight. mwb research’s analysts expect a cautious outlook for FY25, but in mwb research’s view, it is the long-term perspective that counts. BUY with an unchanged target price of EUR 28.50. The full update can be downloaded under https://www.research-hub.de/companies/Cancom%20SE